Skip to content

A Randomized Controlled Trial for Knee Osteoarthritis Treated by Acupotomy under Ultrasound Location of Muscle and Bone

A Randomized Controlled Trial for Knee Osteoarthritis Treated by Acupotomy under Ultrasound Location of Muscle and Bone

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002339
Enrollment
Unknown
Registered
2019-05-15
Start date
2019-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Sponsors

Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) To meet the diagnostic criteria of knee osteoarthritis of American College of Rheumatology; (2) For most days in the past month, knee pain was at least moderate and below (VAS score 7); (3) Aged 40 to 75 years; (4) Subjects stopped taking analgesics and took related drugs only when pain was intolerable, such as analgesics or non-steroidal anti-inflammatory drugs. Subjects were not allowed to take hormone drugs and agreed not to change drugs at will during the course of treatment; (5) Willing to sign informed consent.

Exclusion criteria

Exclusion criteria: (1) those who received hormone therapy in the past three months; (2) Intra-articular hyaluronidase injection in the past six months; (3) Joint irrigation or arthroscopy was performed in the past 1 year; (4) Diseases that hinder the safe participation of experimental design and affect the completion of research, such as severe systemic diseases such as myocardial infarction or stroke, congestive heart failure, severe chronic obstructive pulmonary disease, cancer, diabetes and severe mental illness in the past three months; (5) Physical history or clinical manifestations with bleeding tendency, including the current use of anticoagulants; (6) Inflammatory arthritis (such as rheumatoid arthritis or psoriasis type). Before inclusion, the subjects will be tested for rheumatoid factor, erythrocyte sedimentation rate and anti-O, excluding the possibility of rheumatoid arthritis.

Design outcomes

Primary

MeasureTime frame
VAS;WOMAC;

Countries

China

Contacts

Public ContactCairong Zhang

Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

2003zhangcairong@163.com+86 13270746139

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026